Cannabinoids: Novel medicines for the treatment of Huntington's disease

Recent Patents on CNS Drug Discovery

Volumn 7, Issue 1, 2012, Pages 41-48

  Sagredo, Onintza ^a,b,c   Ruth Pazos, M ^d   Valdeolivas, Sara ^a,b,c   Fernández Ruiz, Javier ^a,b,c  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c INSTITUTO RAMÓN Y CAJAL DE INVESTIGACIÓN SANITARIA IRYCIS   (Spain)

^d HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Cannabinoids; Huntington's disease; Neuroprotection; Sativex

Indexed keywords

ANTINEOPLASTIC AGENT; CANNABINOID; CANNABIS; DEXANABINOL; DRONABINOL; HUNTINGTIN; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; NABILONE; NABIXIMOLS; PLANT EXTRACT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AEROSOL; ALLELE; ANALGESIC ACTIVITY; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; AUTOSOMAL DOMINANT INHERITANCE; BRAIN CORTEX; CACHEXIA; CAG REPEAT; CANADA; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; COGNITIVE DEFECT; CORPUS STRIATUM; DEMENTIA; DRUG MECHANISM; GENOME; HUMAN; HUNTINGTON CHOREA; HYPERKINESIA; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; NAUSEA; NERVE REGENERATION; NEUROPROTECTION; NEW ZEALAND; PAIN; PRIORITY JOURNAL; REVIEW; SPAIN; SPASTICITY; SYMPTOM; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT;

ANIMALS; CANNABINOIDS; DRUG DISCOVERY; HUMANS; HUNTINGTON DISEASE; MODELS, BIOLOGICAL; NEUROPROTECTIVE AGENTS;

EID: 84857394149     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488912798842278     Document Type: Review

References (116)

1. Mechoulam R, Ben-Shabat S. From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: the ongoing story of cannabis. Nat Prod Rep 1999; 16: 131-43.
2. Kogan NM, Mechoulam R. Cannabinoids in health and disease. Dialogues Clin Neurosci 2007; 9: 413-30.
3. Mechoulam R. The pharmacohistory of Cannabis sativa. In: Mechoulam R, editor. Cannabinoids as Therapeutic Agents. Boca Raton: CRC Press, 1986; 1-19.
4. Kalant H. Medicinal use of cannabis: history and current status. Pain Res Manag 2001; 6: 80-91.
5. Gaoni Y, Mechoulam R. The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. J Am Chem Soc 1971; 93: 217-24.
6. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: α9-tetrahydrocannabinol, cannabidiol and α9-tetrahydrocannabivarin. Br J Pharmacol 2008; 153: 199-215.
7. Pertwee RG. Pharmacological actions of cannabinoids. Handb Exp Pharmacol 2005; 168: 1-51.
8. Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988; 34: 605-13.
9. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-4.
10. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-5.
11. Pertwee RG. Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict Biol 2008; 13: 147-59.
12. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Sci 1992; 258: 1946-9.
13. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50: 83-90.
14. Gomes I, Grushko JS, Golebiewska U, Hoogendoorn S, Gupta A, Heimann AS, et al. Novel endogenous peptide agonists of cannabinoid receptors. FASEB J 2009; 23: 3020-9.
15. Wang J, Ueda N. Biology of endocannabinoid synthesis system. Prostaglandins Other Lipid Mediat 2009; 89: 112-9.
16. Fowler CJ. The cannabinoid system and its pharmacological manipulation-a review, with emphasis upon the uptake and hydrolysis of anandamide. Fundam Clin Pharmacol 2006; 20: 549-62.
17. Blankman JL, Simon GM, Cravatt BF. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 2007; 14: 1347-56.
18. Fezza F, De Simone C, Amadio D, Maccarrone M. Fatty acid amide hydrolase: a gate-keeper of the endocannabinoid system. Subcell Biochem 2008; 49: 101-32.
19. Cota D. CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health. Diabetes Metab Res Rev 2007; 23: 507-17.
20. Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M. Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 2009; 89: 309-80.
21. Howlett AC, Bidaut-Russell M, Devane WA et al., The cannabinoid receptor: biochemical, anatomical and behavioral characterization. Trends Neurosci 1990; 13: 420-3.
22. Pandey R, Mousawy K, Nagarkatti M, Nagarkatti P. Endocannabinoids and immune regulation. Pharmacol Res 2009; 60: 85-92.
23. Tóth A, Blumberg PM, Boczán J. Anandamide and the vanilloid receptor (TRPV1). Vitam Horm 2009; 81: 389-419.
24. Ross RA. The enigmatic pharmacology of GPR55. Trends Pharmacol Sci 2009; 30: 156-63.
25. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, et al. International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 2010; 62: 588-631.
26. O'Sullivan SE. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol 2007; 152: 576-82.
27. Heifets BD, Castillo PE. Endocannabinoid signaling and long-term synaptic plasticity. Annu Rev Physiol 2009; 71: 283-306.
28. Matias I, Di Marzo V. Endocannabinoids and the control of energy balance. Trends Endocrinol Metab 2007; 18: 27-37.
29. Ohno-Shosaku T, Tanimura A, Hashimotodani Y, Kano M. Endocannabinoids and retrograde modulation of synaptic transmission. Neuroscientist (in press, 2011).
30. Li C, Jones PM, Persaud SJ. Role of the endocannabinoid system in food intake, energy homeostasis and regulation of the endocrine pancreas. Pharmacol Ther 2011; 129: 307-20.
31. De Laurentiis A, Fernández-Solari J, Mohn C, Zorrilla Zubilete M, Rettori V. Endocannabinoid system participates in neuroendocrine control of homeostasis. Neuroimmunomodulation 2010; 17: 153-6.
32. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Sci 2003; 302: 84-8.
33. Mechoulam R, Shohami E. Endocannabinoids and traumatic brain injury. Mol Neurobiol 2007; 36: 68-74.
34. Fernández-Ruiz J, González S, Romero J, Ramos JA. Cannabinoids in neurodegeneration and neuroprotection. In: Cannabinoids as Therapeutics (MDT), Mechoulam R (ed.), Birkhaüser Verlag, Switzerland, 2005; 79-109.
35. Fernández-Ruiz J, Romero J, Velasco G, Tolón RM, Ramos JA, Guzmán M. Cannabinoid CB2 receptor: a new target for the control of neural cell survival? Trends Pharmacol Sci 2007; 28: 39-45.
36. Fernández-Ruiz J, García C, Sagredo O, Gómez-Ruiz M, de Lago E. The endocannabinoid system as a target for the treatment of neuronal damage. Expert Opin Ther Targets 2010; 14: 387-404.
37. Hansen HH, Schmid PC, Bittigau P, Lastres-Becker I, Berrendero F, Manzanares J, et al. Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. J Neurochem 2001; 78: 1415-27.
38. Shohami E, Cohen-Yeshurun A, Magid L, Algali M, Mechoulam R. Endocannabinoids and traumatic brain injury. Br J Pharmacol 2011; 163: 1402-10.
39. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 2001; 413: 527-531.
40. Fernández-Ruiz J, Pazos MR, García-Arencibia M, Sagredo O, Ramos JA. Role of CB2 receptors in neuroprotective effects of cannabinoids. Mol Cell Endocrinol 2008; 286: S91-6.
41. Ozaita A, Puighermanal E, Maldonado R. Regulation of PI3K/Akt/GSK-3 pathway by cannabinoids in the brain. J Neurochem 2007; 102: 1105-14.
42. van der Stelt M, Di Marzo V. Cannabinoid receptors and their role in neuroprotection. Neuromolecular Med 2005; 7: 37-50.
43. Hampson AJ, Bornheim LM, Scanziani M, Yost CS, Gray AT, Hansen BM, et al. Dual effects of anandamide on NMDA receptormediated responses and neurotransmission. J Neurochem 1998; 70: 671-6.
44. Skaper SD, Buriani A, Dal Toso R, Petrelli L, Romanello S, Facci L, et al. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc Natl Acad Sci USA 1996; 93: 3984-9.
45. Shen M, Thayer SA. Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol Pharmacol 1998; 54: 459-62.
46. Monory K, Massa F, Egertová M, Eder M, Blaudzun H, Westenbroek R, et al. The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 2006; 51: 455-66.
47. Földy C, Neu A, Jones MV, Soltesz I. Presynaptic, activitydependent modulation of cannabinoid type 1 receptor-mediated inhibition of GABA release. J Neurosci 2006; 26: 1465-9.
48. Walter L, Stella N. Cannabinoids and neuroinflammation. Br J Pharmacol 2004; 141: 775-85.
49. Witting A, Stella N. Cannabinoid signaling in glial cells in health and disease. Curr Neuropharmacol 2004; 2: 115-24.
50. Molina-Holgado E, Molina-Holgado F. Mending the broken brain: neuroimmune interactions in neurogenesis. J Neurochem 2010; 114: 1277-90.
51. Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr 2008; 30: 271-80.
52. Shohami E, Mechoulam R. A non-psychotropic cannabinoid with neuroprotective properties. Drug Dev Res 2000; 50: 211-5.
53. Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (-)9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 1998; 95: 8268-73.
54. Marsicano G, Moosmann B, Hermann H, Lutz B, Behl C. Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J Neurochem 2002; 80: 448-56.
55. Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernández-Ruiz J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis 2005; 19: 96-107.
56. García-Arencibia M, González S, de Lago E, Ramos JA, Mechoulam R, Fernández-Ruiz J. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res 2007; 1134: 162-70.
57. García C, Palomo C, García-Arencibia M, Ramos JA, Pertwee RG, Fernández-Ruiz J. Symptom-relieving and neuroprotective effects of the phytocannabinoid α9-THCV in animal models of Parkinson's disease. Br J Pharmacol (in press, 2011).
58. Sagredo O, Ramos JA, Decio A, Mechoulam R, Fernández-Ruiz J. Cannabidiol reduced the striatal atrophy caused by 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors. Eur J Neurosci 2007; 26: 843-51.
59. Lafuente H, Alvarez FJ, Pazos MR, Alvarez A, Rey-Santano MC, Mielgo V, et al. Cannabidiol reduces brain damage and improves functional recovery after acute hypoxia-ischemia in newborn pigs. Pediatr Res (in press, 2011).
60. Iuvone T, Esposito G, Esposito R, Santamaria R, Di Rosa M, Izzo AA. Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J Neurochem 2004; 89: 134-41.
61. Iuvone T, Esposito G, De Filippis D, Scuderi C, Steardo L. Cannabidiol: a promising drug for neurodegenerative disorders? CNS Neurosci Ther 2009; 15: 65-75.
62. Ryan D, Drysdale AJ, Lafourcade C, Pertwee RG, Platt B. Cannabidiol targets mitochondria to regulate intracellular Ca2+ levels. J Neurosci 2009; 29: 2053-63.
63. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72: 971-83.
64. Roos RA. Huntington's disease: a clinical review. Orphanet J Rare Dis 2010; 5: 40.
65. Myers RH. Huntington's disease genetics. NeuroRx 2004; 1: 255-62.
66. Sharp AH, Loev SJ, Schilling G, Li SH, Li XJ, Bao J, et al. Widespread expression of Huntington's disease gene (IT15) protein product. Neuron 1995; 14: 1065-74.
67. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Sci 2001; 293: 493-8.
68. Gauthier LR, Charrin BC, Borrell-Pagès M, Dompierre JP, Rangone H, Cordelières FP, et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 2004; 118: 127-38.
69. Luo S, Rubinsztein DC. Huntingtin promotes cell survival by preventing Pak2 cleavage. J Cell Sci 2009; 122: 875-85.
70. Godin JD, Colombo K, Molina-Calavita M, Keryer G, Zala D, Charrin BC, et al. Huntingtin is required for mitotic spindle orientation and mammalian neurogenesis. Neuron 2010; 67: 392-406.
71. Cattaneo E, Zuccato C, Tartari M. Normal huntingtin function: an alternative approach to Huntington's disease. Nat Rev Neurosci 2005; 6: 919-30.
72. Morfini G, Pigino G, Brady ST. Polyglutamine expansion diseases: failing to deliver. Trends Mol Med 2005; 11: 64-70.
73. Orr HT, Zoghbi HY. Trinucleotide repeat disorders. Annu Rev Neurosci 2007; 30: 575-621.
74. Reiner A, Albin RL, Anderson KD, D'Amato CJ, Penney JB, Young AB. Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci USA 1988; 85: 5733-7.
75. Storey E, Beal MF. Neurochemical substrates of rigidity and chorea in Huntington's disease. Brain 1993; 116: 1201-22.
76. Mann DM, Oliver R, Snowden JS. The topographic distribution of brain atrophy in Huntington's disease and progressive supranuclear palsy. Acta Neuropathol 1993; 85: 553-9.
77. Heinsen H, Strik M, Bauer M, Luther K, Ulmar G, Gangnus D, et al. Cortical and striatal neurone number in Huntington's disease. Acta Neuropathol 1994; 88: 320-33.
78. Han I, You Y, Kordower JH, Brady ST, Morfini GA. Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features. J Neurochem 2010; 113: 1073-91.
79. Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 2011; 10: 83-98.
80. Roze E, Bonnet C, Betuing S, Caboche J. Huntington's disease. Adv Exp Med Biol 2010; 685: 45-63.
81. Rosas HD, Salat DH, Lee SY, Zaleta AK, Hevelone N, Hersch SM. Complexity and heterogeneity: what drives the ever-changing brain in Huntington's disease? Ann NY Acad Sci 2008; 1147: 196-205.
82. Cowan CM, Raymond LA. Selective neuronal degeneration in Huntington's disease. Curr Top Dev Biol 2006; 75: 25-71.
83. Walker FO. Huntington's Disease. Semin Neurol 2007; 27: 143-50.
84. Berardelli A, Noth J, Thompson PD, Bollen EL, Currà A, Deuschl G, et al. Pathophysiology of chorea and bradykinesia in Huntington's disease. Mov Disord 1999; 14: 398-403.
85. Li SH, Li XJ. Huntingtin and its role in neuronal degeneration. Neuroscientist 2004; 10: 467-75.
86. Factor SA, Friedman JH. The emerging role of clozapine in the treatment of movement disorders. Mov Disord 1997; 12: 483-96.
87. Kieburtz K. Antiglutamate therapies in Huntington's disease. J Neural Transm Suppl 1999; 55: 97-102.
88. Butler R, Bates GP. Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nat Rev Neurosci 2006; 7: 784-96.
89. Bonelli RM, Wenning GK. Pharmacological management of Huntington's disease: an evidence-based review. Curr Pharm Des 2006; 12: 2701-20.
90. Lastres-Becker I, de Miguel R, De Petrocellis L, Makriyannis A, Di Marzo V, Fernández-Ruiz J. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease. J Neurochem 2003; 84: 1097-109.
91. Fernández-Ruiz J. The endocannabinoid system as a target for the treatment of motor dysfunction. Br J Pharmacol 2009; 156: 1029-40.
92. Van Laere K, Casteels C, Dhollander I, Goffin K, Grachev I, Bormans G, et al. Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo. J Nucl Med 2010; 51: 1413-7.
93. Glass M, Dragunow M, Faull RL. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neurosci 2000; 97: 505-19.
94. Lastres-Becker I, Hansen HH, Berrendero F, de Miguel R, Pérez-Rosado A, Manzanares J, et al. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease. Synapse 2002; 44: 23-35.
95. Lastres-Becker I, Gómez M, De Miguel R, Ramos JA, Fernández-Ruiz J. Loss of cannabinoid CB1 receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington's disease. Neurotox Res 2002; 4: 601-8.
96. Blázquez C, Chiarlone A, Sagredo O, Aguado T, Pazos MR, Resel E, et al. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. Brain 2011; 134: 119-36.
97. Pintor A, Tebano MT, Martire A, Grieco R, Galluzzo M, Scattoni ML, et al. The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum. Neuropharmacol 2006; 51: 1004-12.
98. Scotter EL, Goodfellow CE, Graham ES, Dragunow M, Glass M. Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease. Br J Pharmacol 2010; 160: 747-61.
99. Dowie MJ, Howard ML, Nicholson LF, Faull RL, Hannan AJ, Glass M. Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice. Neurosci 2010; 170: 324-36.
100. Palazuelos J, Aguado T, Pazos MR, Julien B, Carrasco C, Resel E, et al. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain 2009; 132: 3152-64.
101. Sagredo O, González S, Aroyo I, Pazos MR, Benito C, Lastres-Becker I, et al. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity by limiting the influence of reactive microglia on neuronal homeostasis: relevance for Huntington's disease. Glia 2009; 57: 1154-67.
102. Fernández-Ruiz, J. Use of CB2 receptor agonists for the treatment of Huntington's disease. US20070248702 (2007).
103. Curtis A, Rickards H. Nabilone could treat chorea and irritability in Huntington's disease. J Neuropsychiatry Clin Neurosci 2006; 18: 553-4.
104. Müller-Vahl KR, Schneider U, Emrich HM. Nabilone increases choreatic movements in Huntington's disease. Mov Disord 1999; 14: 1038-40.
105. Curtis A, Mitchell I, Patel S, Ives N, Rickards H. A pilot study using nabilone for symptomatic treatment in Huntington's disease. Mov Disord 2009; 24: 2254-9.
106. Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R, et al. Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav 1991; 40: 701-8.
107. Russo E, Guy GW. A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 2006; 66: 234-46.
108. Wright S. Cannabinoid-based medicines for neurological disordersclinical evidence. Mol Neurobiol 2007; 36: 129-36.
109. Pertwee RG. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 2009; 156: 397-411.
110. Lastres-Becker I, Bizat N, Boyer F, Hantraye P, Fernández-Ruiz J, Brouillet E. Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo. Neuroreport 2004; 15: 2375-9.
111. Sagredo O, Pazos MR, Satta V, Ramos JA, Pertwee RG, Fernández-Ruiz J. Neuroprotective effects of phytocannabinoidbased medicines in experimental models of Huntington's disease. J Neurosci Res 2011; 89: 1509-18.
112. Guy, G., Platt, B. Cannabinoid-containing plant extracts as neuroprotective agents. US20100239693 (2010).
113. Costa B, Trovato AE, Comelli F, Giagnoni G, Colleoni M. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol 2007; 556: 75-83.
114. Costa B, Colleoni M, Conti S, Parolaro D, Franke C, Trovato AE, et al. Oral anti-inflammatory activity of cannabidiol, a nonpsychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. Naunyn Schmiedebergs Arch Pharmacol 2004; 369: 294-9.
115. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Nonpsychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 2009; 30: 515-27.
116. Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO. Cannabidiol-recent advances. Chem Biodivers 2007; 4: 1678-92.